By analyzing two cohorts of ccRCC patients treated with Sunitinib, we showed that female patients in the DKC1-high group was significantly associated with lower response rates accompanied by markedly shortened PFS. This evidence concerns the gene DKC1 and nonpapillary renal cell carcinoma.